Launching innovative biopharma in China | Deloitte Insights
United States
  • Services
    What's New
    • Deloitte's 2020 Global Marketing Trends

      Learn more

    • Register for Dbriefs webcasts

    • Listen to our podcasts

      From tech tips to financial risks

    Tax
    • Global Business Tax Services
    • Global Employer Services
    • Multistate Tax
    • Operations Transformation for Tax
    Consulting
    Audit & Assurance
    • Audit Innovation
    • Accounting Standards
    • Accounting Events & Transactions
    Deloitte Private Company Services
    Mergers & Acquisitions
    • Total M&A Solution
    • Post-merger Integration
    • Divestiture & Separation
    Risk & Financial Advisory
    • Assurance & Internal Audit
    • Cyber Risk
    • Financial Risk, Transactions & Restructuring
    • Forensic
    • Regulatory & Operations Risk
    • Risk Intelligence
    Analytics
    Cloud
  • Industries
    What's New
    • Read our latest thinking

      Visit Deloitte Insights

    • Register for Dbriefs webcasts

    • Industry Outlooks

      Key opportunities, trends, and challenges

    Consumer
    • Automotive
    • Consumer Products
    • Retail, Wholesale & Distribution
    • Transportation, Hospitality & Services
    Energy, Resources & Industrials
    • Industrial Products & Construction
    • Mining & Metals
    • Oil, Gas & Chemicals
    • Power & Utilities
    Financial Services
    • Banking & Capital Markets
    • Insurance
    • Investment Management
    • Real Estate
    Government & Public Services
    • Civil Government
    • Defense, Security & Justice
    • Federal Health
    • International Donor Organizations
    • State, Local & Higher Education
    • Transport
    Life Sciences & Health Care
    • Health Care
    • Life Sciences
    Technology, Media & Telecommunications
    • Technology
    • Telecommunications, Media & Entertainment
  • Insights

    Deloitte Insights
    What's New
    • Deloitte Review

      Looking ahead, staying ahead

    • Daily executive briefing

      Timely insights to inform your agenda.

    • Deloitte Insights app

      Get daily updates on your mobile device

    By topic
    • AI & cognitive technologies
    • Analytics
    • Blockchain
    • Digital transformation
    • Diversity & inclusion
    • Economics
    • Human capital
    • Innovation
    • Leadership
    • Private companies
    • Risk management
    • Strategy
    By sector
    • Automotive
    • Consumer products & retail
    • Financial services
    • Government & public services
    • Health care
    • Industrial products
    • Life sciences
    • Oil, gas & chemicals
    • Power & utilities
    • Technology
    • Telecom, media & entertainment
    • Transportation & hospitality
    Spotlight
    • Daily Executive Briefing
    • Deloitte Review
    • Economic weekly update
    • Future of mobility
    • Future of work
    • Industry 4.0
    • Internet of Things
    • Smart cities
  • Careers
    What's New
    • Life at Deloitte Podcast

      A podcast by our professionals who share a sneak peek at life inside Deloitte.

    • Life at Deloitte Blog

      Discover Deloitte and learn more about our people and culture.

    • Candidate Profile

      Have you already applied for a job? You can now update your candidate profile here.

    Careers
    • Our Purpose
    • Audit & Assurance
    • Consulting
    • Risk and Financial Advisory
    • Tax
    • Internal Services
    Students
    • Undergraduate
    • Advanced Degree
    • Professional Development
    • Recruiting Process
    • On Campus
    Experienced Professionals
    • Recruiting Process
    • Executives
    • Industries
    Job Search
    • Student Jobs
    • Experienced Professional Jobs
    • Recruiting Tips
    • Explore Your Fit
    • Labor Condition Applications
    Life at Deloitte
    • Life at Deloitte Blog
    • Meet Our People
    • Inclusion
    • Corporate Citizenship
    • Leadership Development
    • Empowered Well-Being
    • Deloitte University
    Alumni Relations
    • Update Your Information
    • Events
    • Career Development Support
    • Marketplace Jobs Dashboard
    • Alumni Resources
  • US-EN Location: United States-English  
    • Contact us
    • US-EN Location: United States-English  
      • Contact us
        • Dashboard
        • Bookmarks
        • Content feed
        • Subscriptions
        • Profile/Interests
        • Account settings

      Welcome back

      Still not a member? Join My Deloitte

      Gain the edge in a fast-moving market

      By David Xie, Xiaofeng Li
      • Add to my bookmarks
      • Highlight
      • Download
      • Share
        • Share on Facebook
        • Share on Twitter
        • Share on Linkedin
        • Share by email
      Deloitte Insights
      • By topic
        By topic
        By topic
        • AI & cognitive technologies
        • Analytics
        • Blockchain
        • Digital transformation
        • Diversity & inclusion
        • Economics
        • Human capital
        • Innovation
        • Leadership
        • Private companies
        • Risk management
        • Strategy
      • By sector
        By sector
        By sector
        • Automotive
        • Consumer products & retail
        • Financial services
        • Government & public services
        • Health care
        • Industrial products
        • Life sciences
        • Oil, gas & chemicals
        • Power & utilities
        • Technology
        • Telecom, media & entertainment
        • Transportation & hospitality
      • Spotlight
        Spotlight
        Spotlight
        • Daily Executive Briefing
        • Deloitte Review
        • Economic weekly update
        • Future of mobility
        • Future of work
        • Industry 4.0
        • Internet of Things
        • Smart cities
      • US-EN Location: United States-English  
        • Contact us
          • Dashboard
          • Bookmarks
          • Content feed
          • Subscriptions
          • Profile/Interests
          • Account settings
        5 minute read 15 March 2019

        Gain the edge in a fast-moving market Launching innovative biopharma in China

        5 minute read 15 March 2019
        • David Xie China
        • Xiaofeng Li United Kingdom
        • Add to my bookmarks
        • Highlight
        • Download
        • Share
          • Share on Facebook
          • Share on Twitter
          • Share on Linkedin
          • Share by email
        • 1. Rethink market access and reimbursement
        • 2. Understand the digital ecosystem
        • 3. Revisit the regulatory landscape in China
        • 4. Be agile in the fast-changing health care environment
        • Conclusion

        Biopharma companies looking to launch innovative medicines in China can pull ahead in the race by taking advantage of key cultural and regulatory conditions. Deloitte introduces a series of four articles that break down the dynamics of a successful launch.

        China has swiftly become one of the largest biopharmaceuticals (biopharma) and medical products markets in the world, projected to reach $145-175 billion in sales by 2022.1 Quicker regulatory approval and widening market access are among the profound changes that have made China a significant market for biopharma companies to launch innovative medical products. But the vast majority of firms are often disappointed by their commercial launches in China. The companies that succeed begin their launch preparation and planning early – absorbing a deep understanding of the country’s dynamic system, implementing strong organisational capabilities and developing an agile approach.

        Learn More

        Explore the Launching innovative biopharma in China series

        View the Life Sciences collection

        Subscribe to receive more information about innovative biopharma in China

        In a hurry? Read a brief version from Deloitte Review, issue 25

        Create a custom PDF or download the issue

        Download the Deloitte Insights and Dow Jones app

         

        China’s fast-moving health care industry landscape and unique market characteristics often demand that a biopharma company or biological/ chemical medicine manufacturer adopt a ‘China perspective’, with a launch strategy that differs from those used in the west. Deloitte’s recent experience supporting biopharma companies has enabled us to identify the following four critical areas that support such a strategy and are crucial to a successful launch in China.

        1. Rethink market access and reimbursement

        Market access in China is evolving rapidly. Since 2017 the country has approved a record number of innovative foreign drugs.2 These approvals follow a series of policy moves to provide public funding, enabling a population of 1.4 billion to access new and life-saving drugs – especially cancer therapies. Before that, it was difficult for innovative medicines to achieve reimbursement. From 2001 to 2016, the national reimbursement drug list (NRDL; a list of drugs for which the government pays some or all of the cost) was updated only three times with limited inclusion of innovative medicines.3

        China updated its NRDL in both 2017 and 2018. An important development was a new price negotiation mechanism. Following a small pilot in 2015, 45 medicines were invited into price negotiations in 2017; 36 of those, including some established blockbuster products, reached agreements to join the NRDL.4 However, success came at a cost – an average price cut of 44 per cent. In 2018 another 17 cancer drugs were added to the NRDL with an average 57 per cent discount.5 Drug makers are having to slash prices so that the Chinese government will cover the costs of some advanced treatments.6

        In contrast to the NRDL norm of reimbursing established products, ten of the 17 drugs added in 2018 were new products: a positive sign that reimbursement in China may now happen more quickly. Moreover, subnational payers and private insurers have also been proactive in experimenting and piloting different programmes (such as outcome-based schemes) to enhance patient access.

        The new price negotiation mechanism requires companies to exhaustively explore the options surrounding a potential trade-off of price and/or volumes that can be sold. They must also evaluate the brand opportunity in a more sophisticated way than the traditional assessment for a self-pay market. Companies that want to succeed in launching products must stay on top of the changing dynamics and continue to explore new access options for patients.

        2. Understand the digital ecosystem

        Traditionally, China has had a ‘face-to-face’ business culture. However, thanks to large, government-led infrastructure programmes and investment, the country is now leading the way in digital innovation. Through the widespread adoption of smart devices, and innovative digital applications and tools, China has become a mobile-first economy.

        Patients and physicians are both changing their behaviour in this new digital world. The rise of digital technologies and the associated ecosystem of partnerships are transforming the way a new product is launched and how patients interact with it. For example, vaccine manufacturers have initiated partnerships with local e-commerce platforms to offer vaccination consultations online.

        It is undeniable that digital capability is now critical to a successful launch in this new era. More and more companies are partnering with local digital firms to expand the coverage and depth of market-shaping activities, capture deeper customer insights via ‘big data’ or provide customer solutions that add value beyond the products themselves. Although most companies are still on the journey of embedding digital technologies, those leading the market often have four key attributes driving their success, as shown in Figure 1.

        The four critical areas to consider

        3. Revisit the regulatory landscape in China

        Historically, foreign innovative drugs were delayed by an average of five to seven years before receiving approval in China. The delay was mainly attributed to the slow review process and additional local requirements, such as the mandate that a local study cannot start before the completion of a Phase 2 study outside China.7 In 2017 the China Food and Drug Administration (CFDA) announced a series of regulatory reforms aimed at accelerating marketing authorisation of medical innovations. These included a fast-track approval process and a potential local-study waiver for products targeting rare diseases or diseases with substantial unmet needs.8

        Understanding and using these modified processes has allowed some biopharma companies to shorten the time-to-market in China; there are products that have received CFDA approval within 12 months of approval by the European Medicines Agency and the US Food and Drug Administration. Other companies have yet to update their launch strategies, continuing to view China as a ‘second-wave’ market in clinical programmes and thereby losing competitive advantage. Moreover, there is still considerable ambiguity in how China’s new regulations apply to specific development programmes. Therefore, biopharma companies need an active local regulatory/development team to engage frequently with local authorities, assessing the likelihood of success down each regulatory path.

        4. Be agile in the fast-changing health care environment

        Another key ingredient for launch excellence is having the agility to react to the rapidly evolving health care environment in China, in the face of such countless uncertainties as:

        • budding innovative Chinese newcomers (as of 2018, more than 130 Class I domestic pipeline products were undergoing registration or Phase 3)
        • the trade wars between the US and China
        • deepening health care reform with a growing tiered system
        • changing payers at the subregional and hospital levels and in the private sector.

        Having just one area of uncertainty could easily affect all aspects of a biopharma company, not to mention a specific product launch strategy, in China. In Deloitte’s experience, many multinational companies have not yet established an internal structure or systematic launch framework that would permit an agile approach in China. They apply a generalised approach to developing a road map and key performance index, then encounter difficulties when unexpected market events take place. Global and local teams need to build a more agile collaboration mechanism. They should also embrace enhanced capabilities, such as scenario-based strategic management, to support launch excellence and product cycle management in an ever-changing marketplace.

        Conclusion

        As China’s health care reforms continue, bio-pharma companies are facing an attractive but fast-moving environment. Capitalising on its opportunities requires working with the evolving system in creative ways, starting with early preparation and planning. Explore further insights into China’s market access, digital technologies, regulations and changing health care environment with our full series of articles.

        Explore further insights into China’s market access, digital technologies, regulations and changing health care environment with our full series of articles.

         

        Acknowledgments

        The authors would like to thank An Li of Monitor Deloitte for her contributions to this article.

        Cover image by: Mike Ellis

        Endnotes
          1. Joy Persaud, “Chinese pharma market primed for growth after sweeping reforms”, Pharmaphorum, 25 September 2018. View in article

          2. “2017 new medicines in China eruption: 39 imported foreign medicines go to market and 174 type 1 new medicines in application”, E-med agency, 26 February 2018. View in article

          3. “New NRDL update released after 8 years”, Sina, 24 February 2017. View in article

          4. “MOHRSS released NRDL update”, Ministry of Human Resources and Social Security of the People’s Republic of China, 19 July 2017. View in article

          5. “The National Medical Insurance Bureau issued the results of the special negotiation on the admission of anti-cancer drugs”, CCTV news, 10 October 2018. View in article

          6. “Drugmakers gain more access to China, but at a price”, The Wall Street Journal, 27 November 2018. View in article

          7. “New drug domestic market is accelerated again: The Chinese Food and Drug Administration recognizes overseas clinical data, including generic drugs”, The Observer, 11 July 2018. View in article

          8. “The State Drug Administration issued the Technical Guidelines for Accepting Data on Overseas Clinical Trials of Drugs”, Drug Administration Shanghai, 11 July 2018. View in article

        Show moreShow less

        Topics in this article

        China , Pharmaceutical , Innovation , Digital Health

        LSHC China

        The LSHC team at Deloitte Consulting China supports a multitude of product launches every year. We help our clients prioritize launch assets based on a holistic assessment of external and internal attractiveness factors. Our insights into rapidly changing regulatory policies allow for clinical and regulatory affairs organizations to make informed decisions within accurate regulatory paths when bringing assets to China. We help commercial organizations to develop impactful brand strategy leveraging our industry-leading market excellence methodology and commercial innovation framework, activated by a large network of KOLs and patient organizations. We are also the leader in end-to-end market access planning, including scenario based access strategy, TA level HEOR analytics, as well design and implementation of specific access models and more innovative access contracts.

        Learn more
        Get in touch
        Contact
        • Andrew Yu
        • Deloitte China Life Sciences & Health Care Consulting Leader, Managing partner
        • Deloitte China
        • andryu@deloitte.com.cn
        • +86 21 23166913

        Download Subscribe

        Related

        img Trending

        Will political tensions derail economic gains in Asia Pacific?

        Article 9 months ago
        img Trending

        Survey finds biopharma companies lag in digital transformation

        Article 1 year ago
        img Trending

        Digital R&D: Transforming the future of clinical development

        Article 1 year ago
        img Trending

        The future of real-world evidence

        Article 1 year ago

        Read other articles in the series

        • A new view on biopharma market access in China Article9 months ago
        • A new view on China’s digital health care Article9 months ago

        Share article highlights

        See something interesting? Simply select text and choose how to share it:

        Email a customized link that shows your highlighted text.
        Copy a customized link that shows your highlighted text.
        Copy your highlighted text.

        Gain the edge in a fast-moving market has been added to your bookmarks.

        Gain the edge in a fast-moving market has been removed from your bookmarks.

        An article titled Gain the edge in a fast-moving market already exists in the bookmark library

        Invalid special characters found 
        Forgot password

        OR

        Social login not available on Microsoft Edge browser at this time.

        Connect Accounts

        Connect your social accounts

        This is the first time you have logged in with a social network.

        You have previously logged in with a different account. To link your accounts, please re-authenticate.

        Log in with an existing social network:

        To connect with your existing account, please enter your password:

        OR

        Log in with an existing site account:

        To connect with your existing account, please enter your password:

        Forgot password

        Subscribe

        to receive more business insights, analysis, and perspectives from Deloitte Insights
        ✓ Link copied to clipboard
        • Contact us
        • Search jobs
        • Submit RFP
        • Subscribe to Deloitte Insights
        Follow Deloitte Insights:
        Global Office Directory
        US Office Locations
        Location: US-EN United States-English  
          About Deloitte
          • About us
          • My Deloitte
          • Deloitte Insights
          • Press releases
          • Social media
          • Email subscriptions
          • Submit RFP
          • US office locations
          • Alumni
          • Global office directory
          • Newsroom
          • CRG profiles
          • Dbriefs webcasts
          • Contact us

          Services

          • Tax
          • Consulting
          • Audit & Assurance
          • Deloitte Private Company Services
          • Mergers & Acquisitions
          • Risk & Financial Advisory
          • Analytics
          • Cloud

          Industries

          • Consumer
          • Energy, Resources & Industrials
          • Financial Services
          • Government & Public Services
          • Life Sciences & Health Care
          • Technology, Media & Telecommunications

          Careers

          • Careers
          • Students
          • Experienced Professionals
          • Job Search
          • Life at Deloitte
          • Alumni Relations
          • About Deloitte
          • Terms of Use
          • Privacy
          • Tax Privacy
          • Privacy Shield
          • Deloitte Digital Online Ad Privacy Policy
          • Cookies
          • Legal Information for Job Seekers
          • Labor Condition Applications

          © 2019. See Terms of Use for more information.

          Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee ("DTTL"), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as "Deloitte Global") does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the "Deloitte" name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see www.deloitte.com/about to learn more about our global network of member firms.